These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 24240881

  • 1. Safety and Efficacy of Benzalkonium Chloride-optimized Tafluprost in Japanese Glaucoma Patients With Existing Superficial Punctate Keratitis.
    Suzuki K, Teranishi S, Sagara T, Yoshino H, Nakayama M, Enoki M, Nuno Y, Hirano S, Wakuta M, Takahashi N, Tokuhisa K, Kondo Y, Shiraishi R, Ishida Y, Sonoda KH, Yamaguchi Glaucoma Study Group.
    J Glaucoma; 2015 Aug; 24(6):e145-50. PubMed ID: 24240881
    [Abstract] [Full Text] [Related]

  • 2. Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost.
    Aihara M, Ikeda Y, Mizoue S, Arakaki Y, Kita N, Kobayashi S, NEXTraKT Study Group.
    J Glaucoma; 2016 Jun; 25(6):e610-4. PubMed ID: 25967526
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
    Aihara M, Otani S, Kozaki J, Unoki K, Takeuchi M, Minami K, Miyata K.
    J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
    [Abstract] [Full Text] [Related]

  • 6. Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.
    DuBiner HB, Hubatsch DA.
    BMC Ophthalmol; 2014 Nov 28; 14():151. PubMed ID: 25432143
    [Abstract] [Full Text] [Related]

  • 7. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
    Whitson JT, Trattler WB, Matossian C, Williams J, Hollander DA.
    J Ocul Pharmacol Ther; 2010 Jun 28; 26(3):287-92. PubMed ID: 20578283
    [Abstract] [Full Text] [Related]

  • 8. Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials.
    Cucherat M, Stalmans I, Rouland JF.
    J Glaucoma; 2014 Jan 28; 23(1):e69-75. PubMed ID: 23881267
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The use of benzalkonium chloride in topical glaucoma treatment: An investigation of the efficacy and safety of benzalkonium chloride-preserved intraocular pressure-lowering eye drops and their effect on conjunctival goblet cells.
    Nagstrup AH.
    Acta Ophthalmol; 2023 Dec 28; 101 Suppl 278():3-21. PubMed ID: 38037546
    [Abstract] [Full Text] [Related]

  • 12. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension.
    Crichton AC, Vold S, Williams JM, Hollander DA.
    Adv Ther; 2013 Mar 28; 30(3):260-70. PubMed ID: 23475405
    [Abstract] [Full Text] [Related]

  • 13. Ocular Surface Disease in Glaucoma Patients Randomized to Benzalkonium Chloride-Containing Latanoprost and Preservative-Free Bimatoprost.
    Wu JH, Wang TH, Huang JY, Su CC.
    J Ocul Pharmacol Ther; 2021 Dec 28; 37(10):556-564. PubMed ID: 34610257
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy.
    Konstas AG, Boboridis KG, Kapis P, Marinopoulos K, Voudouragkaki IC, Panayiotou D, Mikropoulos DG, Pagkalidou E, Haidich AB, Katsanos A, Quaranta L.
    Adv Ther; 2017 Jan 28; 34(1):221-235. PubMed ID: 27913991
    [Abstract] [Full Text] [Related]

  • 17. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.
    Bourne RRA, Kaarniranta K, Lorenz K, Traverso CE, Vuorinen J, Ropo A.
    BMJ Open; 2019 Apr 02; 9(4):e024129. PubMed ID: 30944129
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions.
    Kumagami T, Wakiyama H, Kusano M, Kajiyama A, Miura Y, Uematsu M, Yoneda A, Kurihara J, Suzuma K, Kitaoka T.
    J Ocul Pharmacol Ther; 2014 May 02; 30(4):340-5. PubMed ID: 24576066
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.